Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633789 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Phase 2 study of Soft Tissue Sarcoma and Advanced Non-Small-Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 597
- Enrollment target
- 20
- Study locations
NCT00633789: Completed Phase 2 study of Soft Tissue Sarcoma and Advanced Non-Small-Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
NCT00633789 is a Phase 2 study of Soft Tissue Sarcoma and Advanced Non-Small-Cell Lung Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 597 participants, above the 68-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (778% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00633789, a Phase 2 study of Soft Tissue Sarcoma and Advanced Non-Small-Cell Lung Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 597 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib
Conditions Studied
Interventions
- DRUG Placebo
- DRUG brivanib
Study Locations (20)
Other
- Local Institution - Brussels
- Local Institution - Brussels
- Local Institution - Brussels
- Local Institution - Paris
- Local Institution - Paris
- Local Institution - Freiburg im Breisgau
- Local Institution - Halle
- Local Institution - Maastricht
Buenos Aires
- Local Institution - Buenos Aires
- Local Institution - Capital Federal
- Local Institution - Capital Federal
- Local Institution - Capital Federal
Illinois
- University Of Chicago - Chicago
- Northshore Univ. Healthsystem - Evanston
New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Ctr - New York
Maryland
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins - Baltimore
Pennsylvania
- University Of Pennsylvania - Philadelphia
Alberta
- Local Institution - Edmonton
Ontario
- Local Institution - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 597 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT00633789 record still lists
NCT00633789 is an interventional study that assigns participants to a tested intervention. The registered 597 participants enrollment target is mid-sized for trials with a published cap, above the 68-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (778% higher).
The record links to 5 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00633789 names 20 study sites across 8 states, led by Other, Buenos Aires, Illinois.
Frequently Asked Questions
What is clinical trial NCT00633789 about?
NCT00633789 is a clinical study titled "Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types". The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether tha...
What is the current status of trial NCT00633789?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 597 participants. The study started on 2008-06. Estimated completion is 2012-12.
What conditions does trial NCT00633789 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Advanced Non-Small-Cell Lung Cancer, Transitional Cell Carcinoma, Gastric/Esophageal Adenocarcinoma, Pancreatic Cancer Including Ampulla of Vater.
What interventions are being tested in trial NCT00633789?
The interventions under investigation include: Placebo (DRUG), brivanib (DRUG).
Who is sponsoring clinical trial NCT00633789?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00633789 being conducted?
This trial has 20 study locations across Illinois, Maryland, New York, Pennsylvania, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00633789's enrollment target sits among peer trials
597 1st of 55 higher than 55 of 55 other Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02138734 · 596 participants · Phase 1
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- NCT06797245 · 596 participants · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
- NCT07100080 · 596 participants · Phase 2
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia